SEC Form 3 · accession 0000903423-16-001362
ALBIREO PHARMA, INC. · ALBO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Nov 3, 2016
Accepted (ET)
Nov 14, 2016 · 4:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001322505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | holding | — | — | — | 777,096 | I | See Explanation of Responses |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1David Bonderman and James G. Coulter are sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. ("Group Advisors" and, together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnology GenPar II Advisors, LLC, which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of each of (i) TPG Biotechnology Partners II, L.P. ("TPG Biotech II"), which directly holds 568,638 shares of Common Stock ("Common Stock") of Albireo Pharma, Inc. (the "Issuer"), and (ii) TPG Biotech II Reinvest AIV L.P. ("TPG Biotech II Reinvest"), which directly holds 208,458 shares of Common Stock of the Issuer.
- F2Because of the relationship between the Reporting Persons and TPG Biotech II and TPG Biotech II Reinvest, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech II and TPG Biotech II Reinvest. Each of TPG Biotech II, TPG Biotech II Reinvest and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech II's and TPG Biotech II Reinvest's or such Reporting Person's pecuniary interest therein, if any.
- F3Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.
Remarks
(4) The Reporting Persons are jointly filing this Form 3 pursuant to Rule 16a-3(j) under the Exchange Act. (5) Clive Bode is signing on behalf of Messrs. Bonderman and Coulter pursuant to the authorization and designation letters dated June 19, 2015, which were previously filed with the Securities and Exchange Commission.